Age Related Macular Degeneration
Conditions
Keywords
OCT Angiography
Brief summary
Age-related macular degeneration (AMD) is the leading cause of severe and irreversible visual loss and classified blindness in the elderly throughout Europe and the US. Among these patients, about 6%-8% are afflicted with the advanced stages of AMD, which are responsible for the most severe visual loss. There is now convincing evidence that vascular endothelial growth factor (VEGF) is a major trigger for the formation of pathological choroidal vessels, responsible for the development of the neovascular form of AMD. Today, the gold standard for vascular imaging of the retina and diagnosis of CNV is angiography using fluorescein (FLA) or indocyanine green (ICG), which involves injection of the dye into a vein of the arm. In the recent years tremendous enhancements in the field of optical coherence tomography have been achieved. These developments made it possible to visualize the retinal vasculature in a full depth manner without the application of an intravenous marker. The proposed study tests the hypothesis that visualisation of CNV lesion size with non-invasive OCT angiography is not inferior to FLA/ICG angiography in treatment naïve and previously treated AMD patients.
Interventions
OTHERNon-invasive OCT based optical angiography
This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
OTHEROxymap T1
The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
OTHEROCT
non-invasive imaging of retinal and choroidal structures.
OTHERFLA/ICG angiography
Fluorescein Angiography and Indocianine Angiography
Sponsors
Medical University of Vienna
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
\- Patients with active CNV due to AMD as assessed by FLA/ICG angiography within 1 week prior to study inclusion
Exclusion criteria
Any of the following will exclude a patient from the study: * Previous application of intravitreal drugs except anti-VEGF injections * Active intraocular inflammation * Presence of an intraocular disease except AMD and cataract
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in visualization of lesion size between non-invasive OCT based optical angiography and FLA/ICG angiography in treatment-naïve and treated patients with CNV due to AMD. | Participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days |
Secondary
| Measure | Time frame |
|---|---|
| choroidal thickness as assessed with OCT | participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days |
| peripapillarly bloodflow as assessed with Doppler OCT | participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days |
Countries
Austria
Contacts
Primary ContactAndreas Pollreisz, MD
Outcome results
None listed